JP2009514870A5 - - Google Patents

Info

Publication number

JP2009514870A5

JP2009514870A5 JP2008539047A JP2008539047A JP2009514870A5 JP 2009514870 A5 JP2009514870 A5 JP 2009514870A5 JP 2008539047 A JP2008539047 A JP 2008539047A JP 2008539047 A JP2008539047 A JP 2008539047A JP 2009514870 A5 JP2009514870 A5 JP 2009514870A5

Authority

JP

Japan

Prior art keywords

regimen

herceptin

rapamycin

unit

preparation

Prior art date

2006-11-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 229940022353 herceptin Drugs 0.000 claims 16
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 14
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 14
• 229960002930 sirolimus Drugs 0.000 claims 14
• 229950008835 neratinib Drugs 0.000 claims 11
• ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 11
• 239000003814 drug Substances 0.000 claims 10
• 241000124008 Mammalia Species 0.000 claims 9
• 206010028980 Neoplasm Diseases 0.000 claims 8
• 239000000203 mixture Substances 0.000 claims 7
• 230000000118 anti-neoplastic effect Effects 0.000 claims 6
• 150000001875 compounds Chemical class 0.000 claims 6
• 239000002552 dosage form Substances 0.000 claims 5
• 150000003839 salts Chemical class 0.000 claims 5
• 208000035269 cancer or benign tumor Diseases 0.000 claims 4
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 3
• 239000003937 drug carrier Substances 0.000 claims 3
• 238000009472 formulation Methods 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 229960000235 temsirolimus Drugs 0.000 claims 3
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 3
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
• 239000002246 antineoplastic agent Substances 0.000 claims 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
• 230000001225 therapeutic effect Effects 0.000 claims 2
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
• 206010060862 Prostate cancer Diseases 0.000 claims 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
• 229940034982 antineoplastic agent Drugs 0.000 claims 1
• 229940041181 antineoplastic drug Drugs 0.000 claims 1
• 210000003679 cervix uteri Anatomy 0.000 claims 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
• HKVAMNSJSFKALM-CPXURSODSA-N everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-CPXURSODSA-N 0.000 claims 1
• 229910052736 halogen Inorganic materials 0.000 claims 1
• 150000002367 halogens Chemical class 0.000 claims 1
• 201000010536 head and neck cancer Diseases 0.000 claims 1
• 208000014829 head and neck neoplasm Diseases 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 208000016992 lung adenocarcinoma in situ Diseases 0.000 claims 1
• 201000005202 lung cancer Diseases 0.000 claims 1
• 208000020816 lung neoplasm Diseases 0.000 claims 1
• 229940124302 mTOR inhibitor Drugs 0.000 claims 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 claims 1
• 201000000050 myeloid neoplasm Diseases 0.000 claims 1
• 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
• 125000004076 pyridyl group Chemical group 0.000 claims 1
• 125000001424 substituent group Chemical group 0.000 claims 1
• 229930192474 thiophene Natural products 0.000 claims 1
• 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1